AlphAIalphai — Financial news for AI agents
seekingalpha.comJUL 12 min read$OSCR

Oscar Health (OSCR) shares rose after an SEC Form 4 showed CEO and director Mark T

Oscar Health (OSCR) shares rose after an SEC Form 4 showed CEO and director Mark T. Bertolini sold 1.24M Class A shares worth about $35.7M, according to the filing. The stock was reported to have gained as much as ~12.23% during Wednesday’s trading.

Original reporting
seekingalpha.com
Published Jul 1, 2026, 10:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 10:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$OSCR
Neutral
medium confidence
Mentioned
$OSCR
Relevance
6/10
alphai data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

The immediate trading signal is the market’s interpretation of the insider sale, evidenced by OSCR’s reported intraday jump (~12%).

02

Market read

A specific insider-sale disclosure coincided with a sharp stock move, creating short-term sentiment/volatility considerations for OSCR traders.

03

What to watch

The article doesn’t state whether the sale was part of a pre-arranged trading plan, nor does it provide remaining ownership or follow-on insider activity, which can materially change interpretation.

Relevance 6/10Novelty 6/10Timing: same-day reaction to newly released SEC Form 4 (Wednesday)

Background

The piece centers on a newly released SEC Form 4 detailing CEO/Director Mark T. Bertolini’s sale of 1.24M Class A shares (~$35.7M).

Company-level read

Ticker impact

$OSCRNeutralMedium confidence
Context

Oscar Health shares jumped after an SEC Form 4 showed CEO/Director Mark T. Bertolini sold 1.24M Class A shares worth about $35.7M.

Expected impact

Likely elevated volatility around insider-selling headlines; direction may fade unless additional disclosures or fundamentals change.

Evidence & confidence

The article cites a specific, newly released Form 4 sale size and ties it to a same-day rally, implying the market reaction is the actionable element rather than a new operating catalyst.

Market effects

Sector

Limited read-across to the broader health-insurance/insurtech space because the catalyst is company-specific insider activity.

Regional

No clear regional spillover indicated.

Global

No global market linkage described.

Counterpoint

What could challenge this read

The rally despite insider selling could indicate the sale was planned (e.g., diversification/comp taxes) and investors focused on the absence of negative operational news.

Key entities

  • company
    Oscar Health

    Subject of the article; OSCR shares rallied after a newly released Form 4 disclosed CEO/Director share sales.

  • person
    Mark T. Bertolini

    CEO and Director whose Form 4 sale of 1.24M Class A shares (~$35.7M) is cited as the catalyst.

  • regulatory_filing
    SEC Form 4

    Insider transaction disclosure referenced as newly released in the article.

Read at source← All news

Related articles

AUG 7
$OSCRMedAI 8/10

Oscar Health (OSCR) Q2 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q2 2026 revenue of $4.9B, up 70% year over year, and net income of $362M. Effectuated membership rose to 2.96M, and medical loss ratio improved to 79.2%. Management reiterated full-year revenue guidance of $18.7B to $19.0B and raised earnings from operations guidance to $500M to $700M, citing disciplined pricing and favorable prior-period reserves, while noting potential higher churn from CMS eligibility verification.

fool.com6 min
AUG 6
$OSCRMed

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

GoodRx reported Q2 revenue of $200.4M, down 1%, and raised its full-year outlook, citing a projected 70% revenue increase from Pharma Direct. Oscar Health reported first-half 2026 results with revenue up 70% to $4.9B and record profitability, attributing gains to its AI platform and “Oswal” tools. Both cited shifting consumer insurance needs.

pymnts.com5 min
AUG 6
$OSCRMed

Oscar Health, Inc. Q2 2026 Earnings Call Summary

Oscar Health, Inc. reported record first-half profitability with $1 billion net income and improved medical loss ratio, citing disciplined pricing and favorable utilization. The company raised 2026 earnings from operations guidance to $500 million to $700 million, with full-year MLR expected at 81.5% to 82.5% and SG&A ratio 15.6% to 16.1%. It highlighted AI tools and CMS program integrity reviews.

yahoo.com6 min
AUG 6
$OSCRMedAI 8/10

Oscar Health Reports Another Big Profit As Obamacare Member Costs Ease

Oscar Health reported a $361.8 million Q2 profit and $1.04 billion net income for the first six months of 2026, with revenue up 70% year over year to $4.9 billion. Membership rose to 2.9 million. Oscar said its medical loss ratio fell to 79.2% from 91.1% and raised its 2026 outlook, citing cost control and prior-period reserve development.

forbes.com4 min
AUG 6
$OSCRHigh

Oscar Health, Inc. (OSCR): Results of Operations and Financial Condition

Oscar Health, Inc. (OSCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 oscarhealthsecondquarter20.htm EX-99.1 Document Oscar Health, Inc. ir.hioscar.com News Release Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook New York, NY, August 6, 2026 – Oscar Health, Inc. (“Oscar” or the “Compan

SEC EDGAR 8-K6 min